Got­tlieb picked for FDA

Modern Healthcare - - LATE NEWS -

Dr. Scott Got­tlieb, who has of­ten said red tape ham­pers com­pe­ti­tion in the phar­ma­ceu­ti­cal mar­ket, has been nom­i­nated to be the na­tion’s top fed­eral reg­u­la­tor of drugs and de­vices.

The White House last week an­nounced that Pres­i­dent Don­ald Trump was choos­ing Got­tlieb, who has strong ties to Wall Street and the phar­ma­ceu­ti­cal in­dus­try, to lead the U.S. Food and Drug Ad­min­is­tra­tion.

Trump has said he wants to ex­pe­dite what he calls the “slow and bur­den­some” ap­proval of drugs and de­vices at the FDA, which reg­u­lates ev­ery­thing from phar­ma­ceu­ti­cals to elec­tronic cig­a­rettes. Got­tlieb has gen­er­ally sup­ported loos­en­ing the agency’s over­sight of wear­able de­vices and smart­watches.

Got­tlieb, 44, served as a deputy com­mis­sioner of the FDA un­der Pres­i­dent Ge­orge W. Bush. He ear­lier served as a se­nior ad­viser to the CMS ad­min­is­tra­tor. Most re­cently, he’s dab­bled in pun­ditry as a res­i­dent fel­low at the con­ser­va­tive Amer­i­can En­ter­prise In­sti­tute and a part­ner in the ven­ture cap­i­tal firm New En­ter­prise As­so­ci­ates.

Since leav­ing the FDA, Got­tlieb has served as a board mem­ber or ad­viser to at least nine drug and de­vice mak­ers. He’s been a con­sul­tant to Glax­oSmithK­line’s prod­uct in­vest­ment board; a man­ag­ing di­rec­tor at T.R. Win­ston & Co. mer­chant bank, which spe­cial­izes in health­care; and a clin­i­cal as­sis­tant pro­fes­sor at New York Univer­sity School of Medicine. He also is a pol­icy ad­viser to the Na­tional Coali­tion for Cancer Sur­vivor­ship.

As he be­gins his con­fir­ma­tion hear­ings, Got­tlieb may dis­close even more con­nec­tions or fi­nan­cial deals in­clud­ing stocks or other in­vest­ments that might cre­ate a con­flict of in­ter­est.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.